Intravenous introduction into the lumen of an isolated area of a previously released blood vein, followed by immediate long-term compression of this site.
The drug can be used only physicians who possess the technique of sclerotherapy and sufficient experience of the procedure in medical institutions provided that the availability of anti-shock therapy is available. In each case, the doctor uses that technique of compression sclerotherapy, which is most suitable for a specific clinical situation. To obtain the maximum therapeutic effect and reduce the risk of developing adverse events (AEs), the following basic principles of compression sclerotherapy should be observed:
- Before the introduction of the drug, it is necessary to assess the condition of deep veins and the presence of valvular insufficiency (see the section "Contraindications"),
- Before the course of venosclerosis therapy, a trial application of the drug should be performed to identify possible individual intolerance (see section "Special instructions").
- The very first administration of the drug Fibro-vein® is performed in most distal from the planned points. The compression bandage should be applied immediately, before the drug is injected into the adjacent target point.
- Sclerosant should be administered immediately after the release of blood from the intended site of the vein.
- The sclerosant should be kept in an empty and isolated section of the vein for about 30 seconds.
- Compression bandage should be applied immediately. Compression should be adequate and maintained for 6 weeks from the moment of drug administration at the last designated point.
- Optimum compression is achieved by using elastic bandages of medium degree of extensibility and special latex pads to provide local compression,
- To prevent possible damaging effects on the endothelium of deep veins with their subsequent thrombosis,patients are advised to walk for at least 1 hour after the injection. The following daily hourly walks are compulsory.
The choice of drug concentration and needle size depends on the diameter of the varicose vein to be treated.
Fibro-vein solution 30 mg / ml is designed for obliteration of varicose veins of large diameter (1 cm and more).
Fibro-vein solution of 10 mg / ml is used to treat superficial varicose veins with a diameter of up to 1 cm.
Fibro-vein® solutions of 2 mg / ml and 5 mg / ml are used for injective sclerotherapy of intradermal varicose veins and telangiectasias.
In the presence of a widespread widespread varicose process, injections of the solution are repeated 2-10 times at intervals of 3-5 days.
Fibro-vein® solution 30 mg / ml: administered at the rate of 0.5-1.0 ml for every 10 cm of varicose veins. The maximum dose for one treatment session is 4 ml (1.0 ml x 4 points), the recommended needle is 25 G x 5/8 ".
Fibro-vein® solutions of 10 mg / ml and 5 mg / ml: administered at the rate of 0.25-1.0 ml for every 5 cm of varicose veins. The maximum dose for one treatment session is 10 ml, the recommended needle is 27 G x 1/2 ", 30 G x 1/2 ".
Fibro-vein® solution 2 mg / ml: administered at the rate of 0.1-1.0 ml for every 3-5 cm of intradermal varicose veins or telangiectasia.The maximum dose for one treatment session is 10 ml, the recommended needle is 30 G x 1/2 ".
For one treatment session, the drug is injected into 2-6 points of 0.3-0.5 ml each (preferably 1 ml).
If it is necessary to perform stage-by-stage sclerosing treatment, sclerosis of superficial veins starts from the lateral branches, and the introduction into the main venous trunk is performed last. When combined treatment in conjunction with a surgical operation - is introduced into varicose tributaries (after removal of surface trunk shafts).